AQP4 and neuromyelitis optica: Furthermore, monoclonal antibodies such as anti-AQP4 have been shown to be promising agents in the treatment of neuromyelitis optica (NMO) (Tradtrantip et al., 2012) and clinical trials are in progress to evaluate the efficacy of anti-AQP4 IgG in NMO and multiple sclerosis.